Skip to content

Studies of Neurological Paraneoplastic Syndromes

Studies of Neurological Paraneoplastic Syndromes

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00587106
Enrollment
51
Registered
2008-01-07
Start date
1988-04-30
Completion date
2009-03-31
Last updated
2009-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paraneoplastic Neurologic Degenerations (PNDs)

Brief summary

This study is for patients with cancer, a known paraneoplastic syndrome, or neurological problems that suggest a paraneoplastic syndrome.

Detailed description

Patients usually go to their doctors with neurological complaints and later find they have cancer, a known paraneoplastic syndrome, or neurological problems that suggest a paraneoplastic syndrome. Paraneoplastic syndromes are rare conditions in which the immune system is involved in causing brain damage and fighting cancer. Such patients with paraneoplastic neurologic degenerations(PNDs) may have autoantibodies, an antibody or protein the immune system creates that is directed against his or her own proteins. This study aims to better understand PNDS by: * analyzing for autoantibodies in serum and cerebral spinal fluid * analyzing for antigen specificity and for antigens in cancer tissue * comparing PND autoantibodies with those in cancer patients but no PND * comparing PND autoantibodies with those in PND patients but no cancer * studying the immune performance of patients with PNDs As this study is not a treatment study, tissues for this study will only come from procedures necessary for the patient's treatment.

Interventions

None listed

Sponsors

National Institutes of Health (NIH)
CollaboratorNIH
Memorial Sloan Kettering Cancer Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All adults are potentially eligible.

Exclusion criteria

* None.

Design outcomes

Primary

MeasureTime frame
Increase understanding of PNDSOngoing

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026